Guardant Health’s $245M Patent Setback & Its Implications

A Delaware federal court has handed Guardant Health (GH) a $245.2 million final judgment for willful DNA-sequencing patent infringement, imposing ongoing royalties on products that generated roughly 90% of the company’s revenue during the infringement period. The ruling introduces a 6% royalty drag on U.S. sales of 11 products – including flagship tests Guardant360 CDx, […]